Literature DB >> 26260993

Delay in Diagnosis of Spinal Muscular Atrophy: A Systematic Literature Review.

Chia-Wei Lin1, Stephanie J Kalb2, Wei-Shi Yeh3.   

Abstract

BACKGROUND: Spinal muscular atrophy is a rare genetic disease with devastating neurodegenerative consequences. Timing of diagnosis is crucial for spinal muscular atrophy because early diagnosis may lead to early supportive care and reduction in patient and caregiver stress. The purpose of this study was to examine the published literature for diagnostic delay in spinal muscular atrophy.
METHODS: A systematic literature search was conducted in the PubMed and Web of Science databases for studies published between 2000 and 2014 that listed any type of spinal muscular atrophy and without molecular, mouse, or pathology in the keywords. Mean and/or median age of onset and diagnosis and delay in diagnosis was extracted or calculated. All estimates were weighted by the number of patients and descriptive statistics are reported.
RESULTS: A total of 21 studies were included in the final analysis. The weighted mean (standard deviation) ages of onset were 2.5 (0.6), 8.3 (1.6), and 39.0 (32.6) months for spinal muscular atrophy types I, II, and III, respectively, and the weighted mean (standard deviation) ages of confirmed spinal muscular atrophy genetic diagnosis were 6.3 (2.2), 20.7 (2.6), and 50.3 (12.9) months, respectively, for types I, II, and III. For studies reporting both age of onset and diagnosis, the weighted diagnostic delay was 3.6, 14.3, and 43.6 months for types I, II, and III, respectively.
CONCLUSIONS: Diagnostic delay is common in spinal muscular atrophy. The length of delay varied by severity (type) of spinal muscular atrophy. Further studies evaluating this delay and tools such as newborn screening are warranted to end the diagnostic delay in spinal muscular atrophy.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SMA type I; SMA type II; SMA type III; diagnosis delay; diagnostic odyssey; spinal muscular atrophy; systematic review

Mesh:

Year:  2015        PMID: 26260993     DOI: 10.1016/j.pediatrneurol.2015.06.002

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  26 in total

Review 1.  Pharmacotherapy for Spinal Muscular Atrophy in Babies and Children: A Review of Approved and Experimental Therapies.

Authors:  Claudia A Chiriboga
Journal:  Paediatr Drugs       Date:  2022-08-27       Impact factor: 3.930

Review 2.  Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.

Authors:  Helgi Thor Hjartarson; Kristofer Nathorst-Böös; Thomas Sejersen
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

3.  Spinal Muscular Atrophy Type 3 Showing a Specific Pattern of Selective Vulnerability on Muscle Ultrasound.

Authors:  Ryutaro Nakamura; Akihiro Kitamura; Takahito Tsukamoto; Yuhei Otowa; Naoki Okamoto; Nobuhiro Ogawa; Isamu Yamakawa; Hyoh Kim; Mitsuru Sanada; Makoto Urushitani
Journal:  Intern Med       Date:  2021-01-15       Impact factor: 1.271

4.  Clinical Evidence Supporting Early Treatment Of Patients With Spinal Muscular Atrophy: Current Perspectives.

Authors:  Tamara Dangouloff; Laurent Servais
Journal:  Ther Clin Risk Manag       Date:  2019-10-02       Impact factor: 2.423

5.  Newborn screening for spinal muscular atrophy: The views of affected families and adults.

Authors:  Felicity K Boardman; Philip J Young; Frances E Griffiths
Journal:  Am J Med Genet A       Date:  2017-04-04       Impact factor: 2.802

6.  Spinal muscular atrophy type I and the dual role of viruses: An interview with Professor Basil T. Darras, Professor of Neurology (Pediatrics) at Harvard Medical School.

Authors:  Ioannis N Mammas; Demetrios A Spandidos
Journal:  Exp Ther Med       Date:  2018-02-22       Impact factor: 2.447

7.  An overview of the Cure SMA membership database: Highlights of key demographic and clinical characteristics of SMA members.

Authors:  Lisa Belter; Suzanne F Cook; Thomas O Crawford; Jill Jarecki; Cynthia C Jones; John T Kissel; Mary Schroth; Kenneth Hobby
Journal:  J Neuromuscul Dis       Date:  2018

8.  Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening.

Authors:  Jacqueline Glascock; Jacinda Sampson; Amanda Haidet-Phillips; Anne Connolly; Basil Darras; John Day; Richard Finkel; R Rodney Howell; Katherine Klinger; Nancy Kuntz; Thomas Prior; Perry B Shieh; Thomas O Crawford; Douglas Kerr; Jill Jarecki
Journal:  J Neuromuscul Dis       Date:  2018

9.  Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey?

Authors:  Maria Carmela Pera; Giorgia Coratti; Beatrice Berti; Adele D'Amico; Maria Sframeli; Emilio Albamonte; Roberto de Sanctis; Sonia Messina; Michela Catteruccia; Giorgia Brigati; Laura Antonaci; Simona Lucibello; Claudio Bruno; Valeria A Sansone; Enrico Bertini; Danilo Tiziano; Marika Pane; Eugenio Mercuri
Journal:  PLoS One       Date:  2020-03-23       Impact factor: 3.240

10.  Infants Diagnosed with Spinal Muscular Atrophy and 4 SMN2 Copies through Newborn Screening - Opportunity or Burden?

Authors:  Wolfgang Müller-Felber; Katharina Vill; Oliver Schwartz; Dieter Gläser; Uta Nennstiel; Brunhilde Wirth; Siegfried Burggraf; Wulf Röschinger; Marc Becker; Jürgen Durner; Katja Eggermann; Christine Müller; Iris Hannibal; Bernd Olgemöller; Ulrike Schara; Astrid Blaschek; Heike Kölbel
Journal:  J Neuromuscul Dis       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.